BARRECA, MARCO
BARRECA, MARCO
DIPARTIMENTO DI BIOTECNOLOGIE E BIOSCIENZE
Tumour ecosystem and molecular dynamics in clinical triple-negative breast cancer depend on the chemotherapy regimen
2024 Barreca, M; Mariani, M; Dugo, M; Galbardi, B; Valagussa, P; Besozzi, D; Viale, G; Gianni, L; Bianchini, G; Callari, M
Tumour ecosystem and molecular dynamics in clinical triple-negative breast cancer depend on the chemotherapy regimen
2024 Barreca, M; Mariani, M; Dugo, M; Galbardi, B; Valagussa, P; Besozzi, D; Viale, G; Gianni, L; Bianchini, G; Callari, M
Tumour ecosystem and molecular dynamics in clinical triple-negative breast cancer depend on the chemotherapy regimen
2024 Barreca, M; Mariani, M; Dugo, M; Galbardi, B; Valagussa, P; Besozzi, D; Viale, G; Gianni, L; Bianchini, G; Callari, M
Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy
2023 Licata, L; Barreca, M; Galbardi, B; Dugo, M; Viale, G; Gyorffy, B; Karn, T; Pusztai, L; Gianni, L; Callari, M; Bianchini, G
Comparison of early modulation of biological pathways and immune microenvironment by anthracyclines- or taxane-based treatment
2022 Callari, M; Barreca, M; Dugo, M; Galbardi, B; Vigano, L; Locatelli, A; Licata, L; Viale, G; Valagussa, P; Viale, G; Gianni, L; Bianchini, G
Immune milieu associated with PD-L1 status in TNBC is dependent on time of biomarker assessment and treatment received: A secondary analysis of the NeoTRIPaPDL1 trial
2022 Callari, M; Huang, C; Egle, D; Bermejo, B; Zamagni, C; Dugo, M; Thill, M; Anton, A; Barreca, M; Russo, S; Ciruelos, E; Greil, R; Zambelli, S; Gyorffy, B; Smart, C; Biasi, O; Valagussa, P; Viale, G; Gianni, L; Bianchini, G